PL3004061T3 - Związki 3,4-dihydroizochinolin-2(1h)-ylowe - Google Patents

Związki 3,4-dihydroizochinolin-2(1h)-ylowe

Info

Publication number
PL3004061T3
PL3004061T3 PL14732756T PL14732756T PL3004061T3 PL 3004061 T3 PL3004061 T3 PL 3004061T3 PL 14732756 T PL14732756 T PL 14732756T PL 14732756 T PL14732756 T PL 14732756T PL 3004061 T3 PL3004061 T3 PL 3004061T3
Authority
PL
Poland
Prior art keywords
dihydroizochinolin
compounds
Prior art date
Application number
PL14732756T
Other languages
English (en)
Inventor
Christopher David Beadle
David Andrew Coates
Junliang Hao
Jr Joseph Herman Krushinski
Matthew Robert Reinhard
John Mehnert Schaus
Craig Daniel Wolfangel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PL3004061T3 publication Critical patent/PL3004061T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL14732756T 2013-05-30 2014-05-27 Związki 3,4-dihydroizochinolin-2(1h)-ylowe PL3004061T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361828740P 2013-05-30 2013-05-30
US201361905329P 2013-11-18 2013-11-18
PCT/US2014/039494 WO2014193781A1 (en) 2013-05-30 2014-05-27 3,4-dihydroisoquinolin-2(1h)-yl compounds
EP14732756.3A EP3004061B8 (en) 2013-05-30 2014-05-27 3,4-dihydroisoquinolin-2(1h)-yl compounds

Publications (1)

Publication Number Publication Date
PL3004061T3 true PL3004061T3 (pl) 2018-01-31

Family

ID=50983199

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14732756T PL3004061T3 (pl) 2013-05-30 2014-05-27 Związki 3,4-dihydroizochinolin-2(1h)-ylowe

Country Status (37)

Country Link
US (1) US8962654B2 (pl)
EP (1) EP3004061B8 (pl)
JP (2) JP6130590B2 (pl)
KR (1) KR101808933B1 (pl)
CN (1) CN105228985B (pl)
AP (1) AP2015008867A0 (pl)
AU (2) AU2014274435B2 (pl)
BR (1) BR112015029090B1 (pl)
CA (1) CA2912849C (pl)
CL (1) CL2015003444A1 (pl)
CR (1) CR20150622A (pl)
CY (1) CY1119361T1 (pl)
DK (1) DK3004061T3 (pl)
DO (1) DOP2015000289A (pl)
EA (1) EA029220B1 (pl)
ES (1) ES2647086T3 (pl)
GT (1) GT201500334A (pl)
HR (1) HRP20171696T1 (pl)
HU (1) HUE034607T2 (pl)
JO (1) JO3316B1 (pl)
LT (1) LT3004061T (pl)
ME (1) ME02838B (pl)
MX (1) MX373843B (pl)
MY (1) MY180751A (pl)
NZ (1) NZ713809A (pl)
PE (1) PE20152032A1 (pl)
PH (1) PH12015502658B1 (pl)
PL (1) PL3004061T3 (pl)
PT (1) PT3004061T (pl)
RS (1) RS56294B1 (pl)
SG (1) SG11201509310QA (pl)
SI (1) SI3004061T1 (pl)
TN (1) TN2015000514A1 (pl)
TW (2) TWI691488B (pl)
UA (1) UA118759C2 (pl)
WO (1) WO2014193781A1 (pl)
ZA (1) ZA201508213B (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3133070T3 (pl) 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
AR106332A1 (es) * 2015-10-23 2018-01-03 Lilly Co Eli Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
WO2017178377A1 (en) 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
AU2018225556A1 (en) 2017-02-21 2019-10-03 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
EP3418270A1 (en) 2017-06-19 2018-12-26 Universidad Complutense De Madrid Novel biphenylsulfoximines as allosteric modulators of the dopamine d1 receptor
EP3717025B1 (en) 2017-12-01 2021-11-03 UCB Biopharma SRL Imaging agents
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
SG11202106595VA (en) 2018-12-18 2021-07-29 Lilly Co Eli Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
US12358890B2 (en) 2019-07-01 2025-07-15 UCB Biopharma SRL Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator
MY210361A (en) * 2019-07-01 2025-09-13 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
PL4200280T3 (pl) * 2020-10-07 2024-05-20 Eli Lilly And Company Pochodne fenylo-3,4-dihydroizochinolin-2(1h)-ylo-etan-1-onu jako dodatnie modulatory allosteryczne receptora dopaminy d1
US20240043400A1 (en) * 2020-12-03 2024-02-08 UCB Biopharma SRL Octahydroisoquinolinyl Derivatives
KR20230121867A (ko) * 2020-12-18 2023-08-21 유씨비 바이오파마 에스알엘 무정형 고체 분산체
JP7734193B2 (ja) * 2020-12-18 2025-09-04 ユーシービー バイオファルマ エスアールエル 2-(3,5-ジクロロ-1-メチル-インダゾール-4-イル)-1-[(1s,3r)-3-(ヒドロキシメチル)-5-(1-ヒドロキシ-1-メチル-エチル)-1-メチル-3,4-ジヒドロ-1h-イソキノリン-2-イル]エタノンのプロドラッグ
WO2022129303A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Dihydroisoquinolinyl derivatives
CA3202993A1 (en) 2020-12-18 2022-06-23 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
JP7824310B2 (ja) 2021-03-08 2026-03-04 イーライ リリー アンド カンパニー 幻覚及び認知症に関連する精神病の治療におけるメビダレン及び他のd1陽性アロステリックモジュレーターの使用
JP2024509272A (ja) * 2021-03-09 2024-02-29 イーライ リリー アンド カンパニー パーキンソン病の進行を減速させるためのメビダレン及び他のd1ポジティブアロステリック調節因子の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2061972T3 (es) 1988-02-19 1994-12-16 Smithkline Beecham Farma 1,2,3,4-tetrahidroisoquinoleinas, procedimiento para su preparacion y su uso como agonistas kapa-receptores.
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
CA2408486A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
US7601739B2 (en) 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
BRPI0808525A2 (pt) * 2007-03-01 2014-08-19 Janssen Pharmaceutica Nv Compostos de tetraidroisoquinolina como moduladors do receptor de histamina h3
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
RU2014129613A (ru) 2011-12-21 2016-02-10 Актелион Фармасьютиклз Лтд Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
SI3004061T1 (sl) 2017-10-30
CL2015003444A1 (es) 2016-07-15
CY1119361T1 (el) 2018-02-14
JP6387433B2 (ja) 2018-09-05
HRP20171696T1 (hr) 2017-12-29
DK3004061T3 (en) 2017-10-23
NZ713809A (en) 2019-11-29
CR20150622A (es) 2016-01-06
AP2015008867A0 (en) 2015-11-30
EP3004061B8 (en) 2017-10-04
PH12015502658B1 (en) 2018-12-14
US8962654B2 (en) 2015-02-24
PH12015502658A1 (en) 2016-03-07
LT3004061T (lt) 2017-11-27
TN2015000514A1 (en) 2017-04-06
DOP2015000289A (es) 2015-12-31
UA118759C2 (uk) 2019-03-11
PE20152032A1 (es) 2016-01-28
US20140357664A1 (en) 2014-12-04
ES2647086T3 (es) 2017-12-19
GT201500334A (es) 2018-11-23
BR112015029090A2 (pt) 2017-07-25
EA029220B1 (ru) 2018-02-28
BR112015029090B1 (pt) 2023-05-09
EA201592082A1 (ru) 2016-04-29
ZA201508213B (en) 2017-08-30
CN105228985B (zh) 2017-05-10
AU2014274435B2 (en) 2016-07-14
SG11201509310QA (en) 2015-12-30
PT3004061T (pt) 2017-10-19
CA2912849C (en) 2017-05-30
HK1216314A1 (en) 2016-11-04
ME02838B (me) 2018-01-20
JP6130590B2 (ja) 2017-05-17
AU2016238934A1 (en) 2016-10-27
CN105228985A (zh) 2016-01-06
RS56294B1 (sr) 2017-12-29
MY180751A (en) 2020-12-08
WO2014193781A1 (en) 2014-12-04
CA2912849A1 (en) 2014-12-04
JP2016520127A (ja) 2016-07-11
AU2014274435A1 (en) 2015-11-19
KR20160003110A (ko) 2016-01-08
BR112015029090A8 (pt) 2020-03-17
HUE034607T2 (en) 2018-02-28
TWI691488B (zh) 2020-04-21
JO3316B1 (ar) 2019-03-13
JP2017178945A (ja) 2017-10-05
AU2016238934B2 (en) 2017-08-03
TW201940469A (zh) 2019-10-16
EP3004061B1 (en) 2017-08-30
TWI691489B (zh) 2020-04-21
MX373843B (es) 2020-03-25
EP3004061A1 (en) 2016-04-13
MX2015016495A (es) 2016-03-01
KR101808933B1 (ko) 2017-12-13
TW201536745A (zh) 2015-10-01

Similar Documents

Publication Publication Date Title
ZA201905393B (en) Selectively substituted quinoline compounds
IL267031B (en) Selectively converted quinoline compounds
PL3004061T3 (pl) Związki 3,4-dihydroizochinolin-2(1h)-ylowe
LT3060041T (lt) Prostaciklino junginiai
DK2970336T3 (da) Tetrahydropyrrolothiazinforbindelser
BR112016010220A2 (pt) compostos inibidores de autoxatina.
GB201303109D0 (en) Novel pyrimidine compounds
HUE047544T2 (hu) Inszekticid hatású vegyületek
DK2975030T3 (da) Dihydropyridazin-3,5-dion-derivat
PT3016777T (pt) Porta-ferramentas
EP2966074A4 (en) morphinan
IL240904A0 (en) Azetidinyloxyphenylpyrrolidine compounds
FR3001302B1 (fr) .
HRP20180618T1 (hr) Spojevi fluorfenilpirazola
DK2947066T3 (da) Phenoxyalkylaminforbindelse
EP3010923A4 (en) PYRROLOCHINAZOLINVERBINDUNGEN
EP2950789A4 (en) ANTIVIRAL CONNECTIONS
FR3001303B1 (fr) .
HRP20180722T1 (hr) Spoj benzotiofena
ITMI20130606A1 (it) Composti naftoeterodiazolici disostituiti
TH1501007139A (th) สารประกอบ 3,4-ไดไฮโดรไอโซควิโนลิน-2(1h)-อิล
TH1501000810A (th) สารประกอบที่ยับยั้งฟอสโฟไดเอสเทอเรสไทป์ 10a
TH1501000971A (th) สารประกอบพิแรโซโลพิริมิดีน
TH1401007838A (th) สารประกอบฟีนอกซิเอธิลไพเพอริดีน
TH1401007117A (th) สารประกอบเตตระไฮโดรไพราโซโลไพริมิดีน